Drug Profile
HTI 1090
Alternative Names: HTI-1090; SHR 9146Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Atridia; Hengrui Therapeutics; Jiangsu Hengrui Medicine Co.
- Developer Atridia; Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Small molecules
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in China (PO, Tablet)
- 04 Jun 2021 Efficacy and safety data from the phase I PIANO trial in Solid tumours presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
- 28 Sep 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO, Tablet)